Model to evaluate the cost-effectiveness of different antibiotics in the management of community-acquired pneumonia in Germany

References

• Office for National Statistics. Mortality Statistics: 1993 (revised) and 1994. Series DH2 no. 21
   Google Scholar
• Guest JF, Morris A. Community-acquired pneumonia: the annual cost to the National Health Service in the UK. European Respiratory Journal 1997; 10(7): 1530–4
   PubMedGoogle Scholar
• Konietzko N, Fabel H (eds). The German Whitebook, New York, Thieme Stuttgart, 1996
   Google Scholar
• Kauppinen MT, Saikku P, Kujala P et al. Clinical picture of community-acquired Chlamydia pneumoniae pneumonia requiring hospital treatment: a comparison between chlamydial and pneumococcal pneumonia. Thorax 1996; 51(2):185-9
   Google Scholar
• Stevens A, Raftery J (editors). Health Care Needs Assessment: an epidemiologically-based needs assessment review. Oxford: Radcliffe Medical Publications, 1988: 1–86
   Google Scholar
• Marrie TJ, Peeling RW, Fine MJ et al. Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course. Am J Med 1996; 101(5): 508–15
   PubMed Web of Science ®Google Scholar
• Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. New England Journal of Medicine 1997; 336(4): 243–50
   PubMed Web of Science ®Google Scholar
• Geddes AM. Empiric therapy in lower respiratory tract infection - an ongoing challenge. Journal of Chemotherapy 1997’; 9(suppl 3): 5–9
   Google Scholar
• Backhouse RJ, Kapasi M, Noble I et al. Modelling the use of three antibiotics in the management of community-acquired pneumonia. British Journal of Medical Economics 1995; 8: 195–210
   Google Scholar
• van Barlingen HJJ, Nuijten MJC, Volmer T et al. Model to evaluate the cost-effectiveness of different antibiotics in the management of acute bacterial exacerbations of chronic bronchitis. Journal of Medical Economics 1998; 1: 201–218
   Google Scholar
• Balfour JA. Oral ciprofoxacin. Pharma Econ 1993; 3(5): 398–421
   PubMedGoogle Scholar
• Carbon C. Quinolones in the treatment of lower respiratory tract infections. Drugs 1993; 45(suppl 3): 91–7
   Google Scholar
• Chien S-M, Pichotta P, Siepman N et al. Treatment of community-acquired pneumonia. Chest 1993; 103(3): 697–701
   PubMedGoogle Scholar
• Ball P. Efficacy and safety of cefprozil versus other beta-lactam antibiotics in the treatment of lower respiratory tract infections. Eur J Clin Microbiol Infect Dis 1994; 13(10): 851–6
   PubMedGoogle Scholar
• Green JA, Butler T, Todd WM. Randomized double-blind trial of the comparative efficacy and safety of cefpodoxime proxetil and cefaclor in the treatment of community-acquired pneumonia. Current Therapeutic Research 1994; 55(9): 1003–15
   Google Scholar
• Block S, Hedrick J, Hammerschlag MR et al. Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate. Pediatr Infect Dis J 1995; 14(6): 471–7
   PubMedGoogle Scholar
• Hopkins S, Williams D. Five-day azithromycin in the treatment of patients with community-acquired pneumonia. Current Therapeutic Research 1995; 56(9): 915–25
   Google Scholar
• Aubier M, Lode H, Gialdroni-Grassi G et al. Sparfloxacin for the treatment of community-acquired pneumonia: a pooled data analysis of two studies. Journal of Antimicrobial Chemotherapy 1996; 37(suppl A): 73–82
   Google Scholar
• Garrelts JC, Herrinton AM. Cost effective treatment of lower respiratory tract infections. Pharma Econ 1996; 10(1): 36–58
   PubMed Web of Science ®Google Scholar
• Gris P. Once-daily, 3-day azithromycin versus a three-times-daily, 10-day course of co-amoxiclav in the treatment of adults with lower respiratory tract infections: results of a randomized, double-blind comparative study. Journal of Antimicrobial Chemotherapy 1996; 37(suppl C): 93–101
   Google Scholar
• Ortqvist A, Valtonen M, Cars O et al. Oral empiric treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. Chest 1996; 110(6): 1499–506
   PubMed Web of Science ®Google Scholar
• Portier H, May T, Proust A. Comparative efficacy of sparfloxacin in comparison with amoxycillin plus ofloxacin in the treatment of community-acquired pneumonia. Journal of Antimicrobial Chemotherapy 1996; 37(suppl A): 83–91
   Google Scholar
• Bachinger A, Rappenhoner B, Rychlik R. Antibiotic therapy in hospitalized patients with severe pneumonia. Kankenh Artz 1996, 69/11: 479–84
   Google Scholar
• Higuera F, Hidalgo H, Feris J et al. Comparison of oral cefuroxime axetil and oral amoxycillin/clavulanate in the treatment of community-acquired pneumonia. Journal of Antimicrobial Chemotherapy 1996; 37(3); 555–64
   Google Scholar
• Hernandez JM. Clinical efficacy of dirithromycin in patients with bactermic pneumonia. Clin Ther 1997; 18(6): 1128–38
   Google Scholar
• Gruneberg RN, Felmingham D, and the Alexander Project Group. Results of the Alexander Project: a continuing, multicenter study of antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens. Diagnostic Microbiology and Infectious Disease 1996; 25(4): 169–81
   PubMed Web of Science ®Google Scholar
• Grob PR. Antibiotic prescribing practices and patient compliance in the community. Scandinavian Journal of Infectious Diseases 1992; 83: 7–14
   Google Scholar
• Nightingale CH, Quintiliani R. Cost of oral antibiotic therapy. Pharmacotherapy 1997; 17(2): 302–7
   PubMed Web of Science ®Google Scholar
• Davey P, Parker S. Cost effectiveness of once-daily oral antimicrobial therapy. Journal of Clinical Pharmacology 1992; 32: 706–10
   PubMed Web of Science ®Google Scholar
• Coley CM, Li YH, Medsger AR et al. Preferences for home versus hospital care among low risk patients with community-acquired pneumonia. Arch Intern Med 1996; 156(14): 1567–71
   Google Scholar